Artisan Partners Limited Partnership cut its holdings in DexCom, Inc. (NASDAQ:DXCM) by 15.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,676,627 shares of the medical device company’s stock after selling 1,025,908 shares during the period. Artisan Partners Limited Partnership owned about 6.56% of DexCom worth $415,245,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. FMR LLC grew its holdings in DexCom by 9.1% during the 1st quarter. FMR LLC now owns 9,845,408 shares of the medical device company’s stock valued at $834,201,000 after purchasing an additional 823,406 shares during the last quarter. Vanguard Group Inc. grew its holdings in DexCom by 4.2% during the 1st quarter. Vanguard Group Inc. now owns 6,596,294 shares of the medical device company’s stock valued at $558,904,000 after purchasing an additional 263,543 shares during the last quarter. Baillie Gifford & Co. grew its holdings in DexCom by 1.4% during the 1st quarter. Baillie Gifford & Co. now owns 6,212,889 shares of the medical device company’s stock valued at $526,418,000 after purchasing an additional 84,085 shares during the last quarter. BlackRock Inc. grew its holdings in DexCom by 5.5% during the 2nd quarter. BlackRock Inc. now owns 4,391,404 shares of the medical device company’s stock valued at $321,232,000 after purchasing an additional 230,542 shares during the last quarter. Finally, Janus Capital Management LLC grew its holdings in DexCom by 12.2% during the 1st quarter. Janus Capital Management LLC now owns 4,001,971 shares of the medical device company’s stock valued at $339,083,000 after purchasing an additional 436,162 shares during the last quarter.

In related news, EVP Andrew K. Balo sold 3,244 shares of DexCom stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $71.18, for a total value of $230,907.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin R. Sayer sold 6,000 shares of DexCom stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $71.86, for a total transaction of $431,160.00. The disclosure for this sale can be found here. Insiders sold 26,223 shares of company stock valued at $1,881,249 in the last 90 days. Company insiders own 1.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Artisan Partners Limited Partnership Trims Stake in DexCom, Inc. (DXCM)” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/artisan-partners-limited-partnership-trims-stake-in-dexcom-inc-dxcm/1569108.html.

Shares of DexCom, Inc. (NASDAQ:DXCM) traded down 2.85% during midday trading on Friday, hitting $70.29. 824,870 shares of the stock traded hands. The stock has a 50-day moving average of $72.47 and a 200-day moving average of $74.11. DexCom, Inc. has a 52-week low of $57.68 and a 52-week high of $94.79. The company’s market cap is $6.08 billion.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. The firm had revenue of $170.60 million during the quarter, compared to analysts’ expectations of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The business’s quarterly revenue was up 24.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.24) earnings per share. On average, equities analysts predict that DexCom, Inc. will post ($0.77) earnings per share for the current fiscal year.

Several equities analysts recently commented on DXCM shares. Canaccord Genuity reiterated a “buy” rating and set a $90.00 price target on shares of DexCom in a report on Wednesday, June 7th. BidaskClub upgraded shares of DexCom from a “hold” rating to a “buy” rating in a report on Wednesday, June 21st. Cowen and Company reiterated a “buy” rating and set a $90.00 price target on shares of DexCom in a report on Friday, July 14th. BMO Capital Markets reiterated a “buy” rating and set a $105.00 price target on shares of DexCom in a report on Thursday, July 13th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $78.00 price target on shares of DexCom in a report on Wednesday, July 12th. Seven investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $86.87.

DexCom Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.